Nurix Therapeutics Financials - Benzinga

Nurix Therapeutics Inc

NRIXNASDAQ

Trade with Public

Trade with Public

$26.71

-0.24-0.89%

At close: Aug 26, 5:00 PM EST

$26.71

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Nurix Therapeutics Financials

Nurix Therapeutics (NRIX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Nurix Therapeutics Q2 EPS $(0.81) Misses $(0.74) Estimate, Sales $9.043M Miss $16.170M Estimate

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 55.77 percent decrease over losses of $(0.52) per share

Benzinga Newsdesk

PRO
Nurix Therapeutics Q1 EPS $(0.79) Beats $(0.86) Estimate, Sales $6.252M Miss $16.607M Estimate

Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.86) by 8.14 percent. This is a 17.91 percent decrease over losses of $(0.67) per share from

Benzinga Newsdesk

Earnings Scheduled For April 8, 2026

Benzinga Insights

PRO
Nurix Therapeutics Q4 EPS $(0.82) Beats $(0.92) Estimate, Sales $13.577M Miss $14.309M Estimate

Benzinga Newsdesk

Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday

US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results.

Avi Kapoor

PRO
Nurix Therapeutics Q3 EPS $(1.03) Misses $(0.88) Estimate, Sales $7.894M Miss $16.736M Estimate

Benzinga Newsdesk